Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.73 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | KCNH3 | Q9ULD8 | 2/20 | 0.47 |
| ▸ | PDE4A | P27815 | 5/20 | 0.47 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.45 |
| ▸ | AHR | P35869 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | DNM2 | P50570 | 3/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | RAD52 | P43351 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13784076 | 0.93 | KMT2A (0.63) | KMT2ALMNAKCNH3PDE4ANR1I2 | |
| SCHEMBL7862893 | 0.93 | KMT2A (0.83) | KMT2ALMNAKCNH3NR1I2AHR | |
| SCHEMBL11787843 | 0.93 | KMT2A (0.83) | KMT2ALMNAKCNH3NR1I2AHR | |
| SCHEMBL20694824 | 0.91 | KMT2A (0.81) | KMT2ALMNAKCNH3NR1I2AHR | |
| SCHEMBL7100653 | 0.91 | KMT2A (0.80) | KMT2ALMNAKCNH3NR1I2AHR | |
| SCHEMBL20680484 | 0.89 | KMT2A (0.78) | KMT2ALMNAKCNH3NR1I2AHR | |
| SCHEMBL17563553 | 0.89 | KMT2A (0.77) | KMT2ALMNAKCNH3NR1I2AHR | |
| SCHEMBL10912439 | 0.89 | KMT2A (0.77) | KMT2ALMNAKCNH3NR1I2AHR | |
| SCHEMBL7937257 | 0.89 | KMT2A (0.77) | KMT2ALMNAKCNH3NR1I2AHR | |
| SCHEMBL1562316 | 0.89 | KMT2A (0.77) | KMT2ALMNAKCNH3NR1I2AHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4112607-A1 | AMINO LIPID COMPOUND, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | Shenzhen Shenxin Biotechnology Co., Ltd. (CN) | 2023-01-04 | — | — | EP | disclosed |
| US-9346768-B2 | Molecular glasses with functionalizable groups | HER MAJESTY THE QUEEN IN RIGHT OF CANADA AS REPRESENTED BY THE MINISTER OF NATIONAL DEFENSE (CA) | 2016-05-24 | — | — | US | disclosed |
| US-9328076-B2 | Molecular glasses with functionalizable groups | HER MAJESTY IN THE RIGHT OF CANADA AS REPRESENTED BY THE MINISTER OF DEFENSE (CA) | 2016-05-03 | — | — | US | disclosed |
| US-20150232433-A1 | Molecular Glasses With Functionalizable Groups | HER MAJESTY THE QUEEN IN RIGHT OF CANADA AS REPRESENTED BY THE MINISTER OF NATIONAL DEFENCE (CA) | 2015-08-20 | — | — | US | disclosed |
| US-20140005370-A1 | MOLECULAR GLASSES WITH FUNCTIONALIZABLE GROUPS | HER MAJESTY THE QUEEN IN RIGHT OF CANADA AS REPRESENTED BY THE MINISTER OF NATIONAL DEFENCE (CA) | 2014-01-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140005370-A1 | MOLECULAR GLASSES WITH FUNCTIONALIZABLE GROUPS | GNG2, GDI1, F12 | KMT2A 3635/4885LMNA 3537/4885KCNH3 172/4885 |
| US-20150232433-A1 | Molecular Glasses With Functionalizable Groups | GDI1, GNG2, F12 | KMT2A 3732/4885LMNA 3433/4885KCNH3 202/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.